Evidence map›Paper›PMID 17257664›Full record

ArticlePharmacology, biochemistry, and behavior2007

Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze.

Kathleen R Bailey, Maria N Pavlova, Alex D Rohde, John G Hohmann, Jacqueline N Crawley

Open access · greenAbstract read
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 104 citations in OpenAlex.

  1. ZMYND11 Restrains KMT2A to Enable a Neuronal Developmental Program.bioRxiv : the preprint server for biology · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Neurocognitive sparing of desktop microbeam irradiation.Radiation oncology (London, England) · 2017
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kathleen R Baileybaileyka@mail.nih.gov
Maria N Pavlova
Alex D Rohde
John G Hohmann
Jacqueline N Crawley
Behavioral Pharma (United States) · US

Funding

HAMSTER SEPARATION MODEL OF DEPRESSIONZ01MH002179 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI CRAWLEY, JACQUELINE N · 1985 to 2008
$3.4M
NEUROBIOLOGY OF DEPRESSIONZ01MH002177 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI CRAWLEY, JACQUELINE N. · 1985 to 2007
$825k
Intramural NIH HHSNIMH NIH HHS Z01 MH002177-20
6 · The paper itself

Abstract

The neuropeptide galanin has been implicated in anxiety-related behaviors, cognition, analgesia, and feeding in rodents. Neuromodulatory actions of galanin are mediated by three G-protein coupled receptors, GalR1, GalR2, and GalR3. The present study investigates the role of the GalR2 receptor by evaluating behavioral phenotypes of mice with a targeted mutation in the GalR2 gene. A three-tiered behavioral phenotyping approach first examined control measures of general health, body weight, neurological reflexes, sensory abilities and motor function. Mice were then assessed on several tests for cognitive and anxiety-like behaviors. GalR2 null mutants and heterozygotes were not significantly different from wildtype littermates on two cognitive tests previously shown to be sensitive to galanin manipulation: acquisition of the Morris water maze spatial task, and trace cued and contextual fear conditioning, an emotional learning and memory task. Two independent cohorts of GalR2 null mutant mice demonstrated an anxiogenic-like phenotype in the elevated plus-maze. No genotype differences were detected on several other measures of anxiety-like behavior. The discovery of an anxiogenic phenotype specific to the elevated plus-maze, similar to findings in GalR1 null mutants, highlights the potential therapeutic efficacy of targeting GalR1 and GalR2 receptors in treating anxiety disorders.

Indexed as

AnimalsAnxietyBody WeightConditioning, PsychologicalExploratory BehaviorFearFemaleGenotypeHealthHeterozygoteMaleMaze LearningMiceMice, KnockoutMovementPainReceptor, Galanin, Type 2

Identifiers

PMID17257664
PMCPMC1853242
OpenAlexW2072772534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.